5. Oct 2026
Description
(AWP Alliance News) - Natera helped launch AFT-70 NAVIGATE, a global randomized Phase III breast cancer trial that will test whether blood-based MRD monitoring can guide more selective use of CDK4/6 inhibitors in intermediate- to high-risk ER-positive, HER2-negative early disease. Results have not been presented yet and are expected in the future.
The study will compare standard upfront combination therapy against an approach that starts with Genentech's oral SERD giredestrant, then escalates treatment only if Signatera detects residual disease. The primary goal is to show patients can avoid unnecessary added therapy without worsening recurrence outcomes.
AFT plans to enroll more than 2,000 patients across about 200 sites in the US and internationally.
https://www.businesswire.com/news/home/20261005157854/en/
Disclaimer: This news brief was created using generative artificial intelligence. Natera Inc. published the original content used to generate this news brief via Business Wire on October 05, 2026, and is solely responsible for the information contained therein.
